1146 related articles for article (PubMed ID: 23640971)
21. Application of randomized clinical trial data to actual practice: apixaban therapy for reduction of stroke risk in non-valvular atrial fibrillation patients.
Amin A; Stokes M; Wu N; Gatt E; Makenbaeva D; Wiederkehr D; Boulanger L
Curr Med Res Opin; 2013 Oct; 29(10):1253-61. PubMed ID: 23796193
[TBL] [Abstract][Full Text] [Related]
22. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
[TBL] [Abstract][Full Text] [Related]
23. Apixaban versus warfarin in patients with atrial fibrillation.
Granger CB; Alexander JH; McMurray JJ; Lopes RD; Hylek EM; Hanna M; Al-Khalidi HR; Ansell J; Atar D; Avezum A; Bahit MC; Diaz R; Easton JD; Ezekowitz JA; Flaker G; Garcia D; Geraldes M; Gersh BJ; Golitsyn S; Goto S; Hermosillo AG; Hohnloser SH; Horowitz J; Mohan P; Jansky P; Lewis BS; Lopez-Sendon JL; Pais P; Parkhomenko A; Verheugt FW; Zhu J; Wallentin L;
N Engl J Med; 2011 Sep; 365(11):981-92. PubMed ID: 21870978
[TBL] [Abstract][Full Text] [Related]
24. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.
Halvorsen S; Atar D; Yang H; De Caterina R; Erol C; Garcia D; Granger CB; Hanna M; Held C; Husted S; Hylek EM; Jansky P; Lopes RD; Ruzyllo W; Thomas L; Wallentin L
Eur Heart J; 2014 Jul; 35(28):1864-72. PubMed ID: 24561548
[TBL] [Abstract][Full Text] [Related]
26. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial.
Al-Khatib SM; Thomas L; Wallentin L; Lopes RD; Gersh B; Garcia D; Ezekowitz J; Alings M; Yang H; Alexander JH; Flaker G; Hanna M; Granger CB
Eur Heart J; 2013 Aug; 34(31):2464-71. PubMed ID: 23594592
[TBL] [Abstract][Full Text] [Related]
28. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
[TBL] [Abstract][Full Text] [Related]
29. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
[TBL] [Abstract][Full Text] [Related]
31. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.
Hijazi Z; Hohnloser SH; Andersson U; Alexander JH; Hanna M; Keltai M; Parkhomenko A; López-Sendón JL; Lopes RD; Siegbahn A; Granger CB; Wallentin L
JAMA Cardiol; 2016 Jul; 1(4):451-60. PubMed ID: 27438322
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
36. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial.
Flaker GC; Eikelboom JW; Shestakovska O; Connolly SJ; Kaatz S; Budaj A; Husted S; Yusuf S; Lip GY; Hart RG
Stroke; 2012 Dec; 43(12):3291-7. PubMed ID: 23033347
[TBL] [Abstract][Full Text] [Related]
37. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
[TBL] [Abstract][Full Text] [Related]
38. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Eikelboom JW; O'Donnell M; Yusuf S; Diaz R; Flaker G; Hart R; Hohnloser S; Joyner C; Lawrence J; Pais P; Pogue J; Synhorst D; Connolly SJ
Am Heart J; 2010 Mar; 159(3):348-353.e1. PubMed ID: 20211294
[TBL] [Abstract][Full Text] [Related]
39. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial.
Van Spall HG; Wallentin L; Yusuf S; Eikelboom JW; Nieuwlaat R; Yang S; Kabali C; Reilly PA; Ezekowitz MD; Connolly SJ
Circulation; 2012 Nov; 126(19):2309-16. PubMed ID: 23027801
[TBL] [Abstract][Full Text] [Related]
40. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial.
Dalgaard F; Mulder H; Wojdyla DM; Lopes RD; Held C; Alexander JH; De Caterina R; Washam JB; Hylek EM; Garcia DA; Gersh BJ; Wallentin L; Granger CB; Al-Khatib SM
Circulation; 2020 Jan; 141(1):10-20. PubMed ID: 31747786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]